kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Mouse PD-1 / PDCD1, Fc Tag,  Avi Tag (Avitag™), 25µg  

Recombinant Biotinylated Mouse PD-1 / PDCD1, Fc Tag, Avi Tag (Avitag™), 25µg

MABSol® Recombinant Biotinylated Mouse PD-1 / PDCD1, AA Leu 25 - Gln 167, expressed from human HEK293 cells, Fc Tag, Fc,Avitag™ (MALS Verified)

recombinant, mouse, biotinylated, protein, PDCD1,PD1,CD279,SLEB2

More details


Availability: within 7 days

455,00 €

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Recombinant MABSol® Biotinylated Mouse PD-1, Fc Tag (PD1-M82F4) is expressed from human HEK293 cells. It contains AA Leu 25 - Gln 167 (Accession # NP_032824).
Predicted N-terminus: Leu 25

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 44.6 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Passed as determined by the HABA assay / binding ELISA.

>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Please refer to product data sheet.

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
Day, Sridharan, Lynam et al
BMC Cancer (2022) 22 (1), 1324
(2) "Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1
Yamaguchi, Atarashi, Yoshimura et al
BMC Cancer (2022) 22 (1), 1325
(3) "Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer
Pei, Wu, Zhao et al
Clin Colorectal Cancer (2022)
Showing 1-3 of 25492 papers.


PD-L1-based cancer vaccine elicits antitumor immunity in a mouse melanoma model
Authors: Z Lin, et al
Journal: Molecular Therapy: Oncolytics 2019
Application: PD-L1 PD-1 Blockade assay (ELISA)